Fibrosis changes following viral clearance and its relation to HCC

Yükleniyor...
Küçük Resim

Tarih

2022

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Iris Publishers

Erişim Hakkı

info:eu-repo/semantics/openAccess

Araştırma projeleri

Organizasyon Birimleri

Dergi sayısı

Özet

Globally, about 290 000 people died from hepatitis C (HCV) in 2019, mostly from cirrhosis and hepatocellular carcinoma (HCC). Less than a decade, direct-acting antivirals (DAAs) replaced interferon-based therapies in treatment protocols and sustained virologic response (SVR) rates exceeded 95%. However, it is not clear yet whether HCV eradication by DAAs can reverse fibrosis or cirrhosis substantially, reduce the risk of developing HCC in the long term. In this review was aimed to summarizes the evidence for reversibility or progression of fibrosis following HCV clearance by DAAs, subsequently its impact on developing de nova HCC. For this purpose, cohorts in which patients achieved SVR, have paired liver stiffness measurements obtained by transient elastography were reviewed and results discussed.

Açıklama

Anahtar Kelimeler

HCV Infection, Hepatocellular Carcinoma, Fibrosis, Sustain Virologic Response, Direct-Acting Antivirals, Liver Stiffness

Kaynak

Academic Journal of Gastroenterology & Hepatology (AJGH)

WoS Q Değeri

Scopus Q Değeri

Cilt

3

Sayı

3

Künye

Yılmaz, N., Yılmaz, U. E., Tanrıverdi, Ö., & Örmeci, N. (2022). Fibrosis changes following viral clearance and its relation to HCC. Academic Journal of Gastroenterology & Hepatology (AJGH), 3(3), pp. 1-5. https://doi.org/10.33552/AJGH.2022.03.000564